Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients
Muhammad Bilal, Michael Zöller, Uwe Fuhr, Ulrich Jaehde, Sami Ullah, Uwe Liebchen, Sören Büsker, Johannes Zander, Baharak Babouee Flury, Max Taubert
Abstract
and a PTA of 90%, a dose of 1,333 mg q8h was found to be related to a probability of neurotoxicity of ≤20% and to cover MICs up to 2 mg/L. Continuous infusion appears to be superior to other dosing regimens by providing higher efficacy and a low risk of neurotoxicity. The model makes it possible to improve the predicted balance between cefepime efficacy and neurotoxicity in critically ill patients. (This study has been registered at ClinicalTrials.gov under registration no. NCT01793012).
Topics & Concepts
CefepimeCritically illMedicineNeurotoxicityPharmacokineticsRegimenDosingIntensive care medicinePopulation pharmacokineticsPopulationPharmacologyInternal medicineToxicityAntibioticsBiologyEnvironmental healthMicrobiologyAntibiotic resistanceImipenemAntibiotics Pharmacokinetics and EfficacyEpilepsy research and treatmentAnesthesia and Sedative Agents